Treatment to render implants resistant to diabetes
Disclosed is a medical device treated with a phenolic compound and a process for treating a device with the phenolic compound. For example, a collagen or elastin-based scaffold can be treated with pentagalloyl glucose (PGG). The treated scaffold can become resistant to glycoxidative stress associated with advanced glycation end products (AGEs) that are present in a hyperglycemic environments associated with diabetes mellitus. The treated scaffold can exhibit a reduced increase in stiffness as compared to an untreated scaffold. The treated scaffold can also exhibit reduced inflammation without negatively affecting the ability of the scaffold to remodel in vivo.
1. A method for rendering an implant resistant to diabetes comprising applying a phenolic compound to the implant by immersing the implant in a treatment solution containing a carrier and the phenolic compound, wherein the phenolic compound is present in the treatment solution at a concentration ranging from about 0.0001 w/v % to about 10 w/v %, wherein the phenolic compound comprises a hydrophobic core and at least one phenolic group joined to the hydrophobic core, further wherein the phenolic compound is pentagalloylglucose and the solution has a pH between about 4 and about 9, wherein the phenolic compound inhibits binding of advanced glycation end products to the implant.
2. The method of claim 1 , further comprising implanting the implant into a subject.
3. The method of claim 1 , wherein the implant is implanted into a diabetic environment.
4. The method of claim 1 , wherein the phenolic compound inhibits degradation of the implant.
5. A composition for rendering an implant resistant to diabetes comprising:
between about 00001 w/v % and about 10 w/v % of a phenolic compound, the phenolic compound comprising a hydrophobic core and at least one phenolic group joined to the hydrophobic core; further wherein the phenolic compound is pentagalloylglucose, wherein the phenolic compound inhibits binding of advanced glycation end products to the implant; and
a carrier;
wherein the composition has a pH between about 4 and about 9.
6. The composition of claim 5 , wherein the phenolic compound comprises one or more double bonds.
7. The composition of claim 5 , wherein the composition has a pH of between about 5.5 and about 7.4.
8. The composition of claim 5 , wherein the composition comprises less than about 5% free gallic acid residue.
9. An implant that is resistant to diabetes, the implant comprising a scaffold treated with a solution comprising about 0.0001 w/v % and about 10 w/v % of a phenolic compound, the phenolic compound comprising a hydrophobic core and at least one phenolic group joined to the hydrophobic core, further wherein the phenolic compound is pentagalloylglucose, wherein the phenolic compound inhibits binding of advanced glycation end products to the implant.
10. The implant of claim 9 , wherein the implant is a collagen-based scaffold or an elastin-based scaffold.
11. The implant of claim 9 , wherein the implant is a replacement heart valve.
12. The implant of claim 11 , wherein the implant is a replacement blood vessel.
13. The implant of 12 , wherein the replacement blood vessel is a decellularized artery.
14. The implant of claim 9 , wherein the phenolic compound comprises one or more double bonds.